PPARG and triple-negative breast carcinoma: In estrogen receptor (ER)- and progesterone receptor (PR)-positive cells, ER/PR-negative and human epidermal growth factor receptor (HER2)-positive cells, and triple-negative breast cancer cells, it has been reported that ligand-activated PPARγ modulates the activation of tumorigenic cascades, leading to inhibition of cell growth, migration, invasiveness, and metastatic properties [18,19,20,21,22].